Loading clinical trials...

COMPLETED

Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution

Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 and Its Resolution

NCT04664023•Poitiers University Hospital

View on ClinicalTrials.gov

Summary

Prospective study to describe the immunological, metabolic and serologic profile in the acute and post acute phases of Coronavirus disease (COVID-19)

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•adult patient
•Patient with Covid-19 confirmed by RT-PCR, supported by Poitiers hospital
•Patient came for RT-PCR test at the drive of the hospital, or hospitalised in one of the Covid-19 departments of the Poitiers hospital (geriatry, infectious and tropical diseases, medical resuscitation and continuous care unit)
•informed consent signed by the patient or a trusted or immediate person after clear and loyal information on the study
•adult patient
•subject wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine
•informed consent signed by the volunteer after clear and loyal information on the study

Exclusion Criteria

•minor patient
•patient having had syptoms for more than 8 days
•patient already enrolled in another study regarding immunomodulators
•patient not benefiting from a Social Security scheme or not benefiting from it through a third party
•patient benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, adult under legal protection
•minor patient
•subject having had COVID-19 documented by a positive RT-PCR test or serology
•subject already vaccinated against COVID-19 (complete or partial vaccinal scheme)
•patient not benefiting from a Social Security scheme or not benefiting from it through a third party
•patient benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, adult under legal protection

Locations (1)

C.H.U.de Poitiers

Poitiers, France

Key Dates

Start Date

December 9, 2020

Primary Completion Date

June 19, 2023

Completion Date

June 19, 2023

Last Updated

June 23, 2023

Enrollment

130

ACTUAL participants

Conditions

Covid19

Interventions

Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection.

PROCEDURE

Blood collection at 1st injection of vaccine against COVID-19, at at second injection of vaccine, at Month 1, Month 2, Month 6 and Month 12 after second injection of vaccine for volunteers

PROCEDURE

The Effect of the Covid-19 Pandemic Among Operated Patients

NCT04525716

Covid19Surgery

View study

RECRUITINGPHASE3

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

NCT03188796

Critical IllnessVitamin D Deficiency+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 23, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution

Inclusion Criteria

Exclusion Criteria

The Effect of the Covid-19 Pandemic Among Operated Patients

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

Covid-19 and Influenza Oral Vaccine Study

Conversations You Want About Corona Virus Disease (COVID-19)

Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19

COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy